NEW YORK, March 16, 2018 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aerohive Networks, Inc. (NYSE:HIVE) between November 1, 2017 and January 16, 2018, both dates inclusive (“Class Period”) of the March 20, 2018 lead plaintiff deadline in the first filed class action commenced by the firm. The lawsuit seeks to recover damages for Aerohive investors under the federal securities laws.
To join the Aerohive class action, go to http://www.rosenlegal.com/cases-1272.html or call Phillip Kim, Esq. or Zachary Halper, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) there were underlying sales execution issues that were uncovered at the end of the third quarter of 2017; (2) consequently, Aerohive’s revenue guidance for the fourth quarter of 2017 was overstated; and (3) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 20, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1272.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Zachary Halper of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Zachary Halper, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com


SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch
Jetstar to Charge for Overhead Cabin Bags From February
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns
DeepSeek to Raise AI API Prices as Demand for New Models Surges
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 



